Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of COVID-19 and malaria coinfection on clinical outcomes: a retrospective cohort study

Rasha Hussein1, 2, 3, 4, Murilo Guedes3, Nada Ibraheim1, Mazin M. Ali1, Amal El-Tahir2, Nahla Allam4, 5, Hussain Abuakar1, Roberto Pecoits-Filho3, 6, Peter Kotanko7, 8, *

1) Universal COVID-19 Treatment Centre, Ministry of Health, Khartoum State, Sudan
2) Ministry of Health, Khartoum State, Sudan
3) School of Medicine, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil
4) Soba University Hospital, Khartoum, Sudan
5) Faculty of Medicine, Al Neelain University, Khartoum, Sudan
6) Ann Arbor Research Collaborative for Health, Ann Arbor, MI, United States
7) Renal Research Institute, New York, NY, USA
8) Icahn School of Medicine at Mount Sinai, New York, NY, USA

Objectives: Despite the possibility of concurrent infection with COVID-19 and malaria, little is known about the clinical course of coinfected patients. We analysed the clinical outcomes of patients with concurrent COVID-19 and malaria infection.

Methods: We conducted a retrospective cohort study that assessed prospectively collected data of all patients who were admitted between May and December 2020 to the Universal COVID-19 treatment center (UCTC), Khartoum, Sudan. UCTC compiled demographic, clinical, laboratory (including testing for malaria), and outcome data in all patients with confirmed COVID-19 hospitalized at that clinic. The primary outcome was all-cause mortality during the hospital stay. We built proportional hazard Cox models with malaria status as the main exposure and stepwise adjustment for age, sex, cardiovascular comorbidities, diabetes, and hypertension.

Results: We included 591 patients with confirmed COVID-19 diagnosis who were also tested for malaria. Mean (SD) age was 58 (16.2) years, 446/591 (75.5%) were males. Malaria was diagnosed in 270/591 (45.7%) patients. Most malaria patients were infected by Plasmodium falciparum (140/270; 51.9%), while 121/270 (44.8%) were coinfected with Plasmodium falciparum and Plasmodium vivax. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days for patients with and without concurrent malaria, respectively. In the fully adjusted Cox model, patients with concurrent malaria and COVID-19 had a greater mortality risk (hazard ratio 1.43, 95% confidence interval 1.21-1.69).

Discussion: Coinfection with COVID-19 and malaria is associated with increased all-cause in-hospital mortality compared to monoinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Introduction

The COVID-19 pandemic disproportionately affects low- and middle-income countries [1, 2]. In Sudan, a Sub-Saharan low- and middle-income country, poor healthcare literacy and the spread of false information further compound the impact of COVID-19 [3].

Fighting COVID-19 in regions where malaria is endemic has been affected by ecological studies suggesting that countries with higher malaria incidence tend to have lower COVID-19 mortality and by cross-sectional analyses reporting that patients previously exposed to malaria may have a better prognosis [4, 5], based on the hypothesis that immunological memory against Plasmodium falciparum may mitigate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [6, 7]. Also, the suggestion that hydroxychloroquine, an anti-malarial drug, could be effective against SARS-
SARS-CoV-2 has supported the notion that patients with SARS-CoV-2 previously exposed to malaria may have better outcomes [8–10]. Nevertheless, the impact of malaria on COVID-19 clinical outcomes remained unaddressed by longitudinal studies [10]. We therefore explored the impact of malaria coinfection on all-cause in-hospital mortality among patients with severe COVID-19.

**Methods**

**Study design, setting, and participants**

We report results of a retrospective cohort study that assessed prospectively collected data. The study questions were formulated prior to data collection. We reviewed records of all patients who were admitted between May and December 2020 to the Universal COVID-19 Treatment Center (UCTC), Khartoum, Sudan. UCTC is the largest COVID-19 clinic in Sudan. It receives only critically-ill patients from hospitals located in Khartoum state and beyond, primary isolation centers, and home isolation. All admitted patients had either COVID-19 confirmed by RT-PCR or suspected by clinical presentation and chest computer tomography. On admission, all patients without previously confirmed COVID-19 were tested by SARS-CoV-2 RT-PCR from nasopharyngeal and/or oropharyngeal swabs.

Malaria infection was screened by both an antigen-based rapid diagnostic test (RDT) and microscopic confirmation of Plasmodium falciparum (PF) and/or Plasmodium vivax (PV).

The Ecotest Malaria PF/Pan Rapid Test Device (MAL-W23M, CTK Biotech, Poway, CA, USA) is a chromatographic immunoassay for rapid qualitative determination of antigen in whole blood. This test depends on the presence of PF histidine-rich protein II specific to PF and plasmodium lactate dehydrogenase specific to PV in human blood sample; it has been applied with thin or thick microscopy on clinical samples. The results showed sensitivity and specificity of 99.9% and over 99%, respectively, relative to microscopy. All RDTs were maintained at room temperature until first use. RDTs were re-tested using RDT for malaria testing was available in 591 patients, constituting the final analytical cohort. All 591 patients with confirmed COVID-19 who were tested for malaria were included in this study. Patients who were diagnosed with malaria before admission (n = 13), were re-tested using RDT and microscopy. Per our laboratory’s experience, the Ecotest is accurate and performs well in low parasite density.

Demographic, clinical, laboratory, and outcome data were extracted from the medical records and entered into an electronic, study-specific database. Steps to ensure data integrity and privacy were implemented.

**Ethics statement**

The study proposal was submitted to the Research Administration at the State Ministry of Health (MOH), Khartoum. Expedited review was conducted by the MOH Ethics Review Committees and approval was granted (protocol COVID-19/001/2020).

**Exposure**

The primary exposure was coinfection with malaria and SARS-CoV-2, as defined above. In additional exploratory analyses, exposures were infection by various malaria species, namely PF, PV, and infection with both PF and PV. Malaria case severity was classified according to the World Health Organization (WHO) criteria (Table S1)[11].

**Outcomes**

**Primary outcome**

The primary outcome was the all-cause in-hospital mortality. Time-at-risk started at hospital admission and ended either at the date of death or hospital discharge. As sensitivity analysis, start time at risk was changed to the onset of COVID-19 symptoms.

**Exploratory outcomes**

Exploratory outcomes were the intensive care unit/ICU admission, need for mechanical ventilation, acute kidney injury (AKI), and kidney replacement therapy. AKI was defined per Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [12].

**Statistical analysis**

Continuous data are summarized as mean and standard deviation (SD) or as median and interquartile range (IQR). Differences between continuous variables are estimated by student’s t-test or Wilcoxon test. Categorical variables are summarized as proportions. Differences across groups are estimated using \( \chi^2 \) or Fisher’s exact tests. Event rates are calculated as incident rates per 1000 person-days of follow-up. Kaplan Meier survival curves are compared using the log-rank test. CI are reported with 95% confidence level.

For the primary outcome, all-cause in-hospital mortality, proportional hazard Cox models are built with malaria status as the main exposure. Models are built stepwise with incremental covariate adjustments made according to \( a \) priori selected variables based on causal assumptions between the exposure and the outcome. Accordingly, the first adjustment set includes age and sex; further adjusted models include cardiovascular comorbidities, diabetes, and hypertension as covariates.

We use generalized estimating equations with independence working covariance structure to estimate the associations between malaria on survival. Generalized estimating equations models are used to estimate population average effects in the presence of correlations between analysis units. In this study, we use geographical location as the cluster.

Proportional hazards assumptions are tested by inspection of Kaplan-Meier curves and testing log(time) interaction with malaria status. Effect modification of the Khartoum region on the malaria exposure is tested by including an interaction term between region and malaria in the fully adjusted model. Additionally, effect modification by age is tested by an interaction term between median age and malaria in the fully adjusted model. Missingsness is assumed to be completely at random and a complete case analysis is performed. Secondary outcomes are modelled using logistic regression. Adjusted ORs are estimated in models including age, sex, hypertension, diabetes, and cardiovascular diseases as covariates. Sensitivity analysis according to malaria severity is performed.

All analyses are performed using R software 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

**Results**

Between May and December 2020, 638 patients were admitted to UCTC in Khartoum, Sudan. Malaria testing was available in 591 (92.6%) patients, constituting the final analytical cohort. All 591
were present in almost all patients in both groups, while cough patients with malaria (13.9% vs. 26.8%). At clinical presentation (Table S4). More than one third presented with renal impairment, acidosis, prostration, and hyperparasitemia at different other than those defined by the WHO criteria (Tables S4 and S5). More patients in the severe malaria group needed oxygen support (95%) as compared to non-severe malaria (91%) and to those without malaria diagnosis (89%). Oxygen flow rates were 11.3 (±4.6), 9.3 (±4.7), and 10.5 (±4.8) L/min for severe malaria, non-severe malaria, and non-malaria groups, respectively. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days in the malaria and non-malaria groups, respectively (Fig. 2). Median length of hospital stay was 21 days (IQR: 14–28) for the malaria group and 20 days (IQR: 15–28) for the non-malaria group (p = 0.49; Wilcoxon test). The median period between symptom onset and hospital admission was 6 days (IQR: 5–9) in the malaria group and 8 days (IQR: 5–11) in the non-malaria group (p = 0.005; Wilcoxon test).

**Table 2** displays the hazard ratios (HRs) for all-cause in-hospital mortality, the primary outcome, in models with stepwise adjustments for potential confounders. In general, individuals with malaria coinfection were at greater risk of mortality in both unadjusted and adjusted analyses (fully adjusted model: HR 1.43, 95% CI 1.21–1.69). Coinfection with PF (n = 140) was associated with an about 50% increased mortality (fully adjusted model: HR 1.45, 95% CI 1.11–1.85). The risk was comparable for a combined infection with PF and PV (n = 121; fully adjusted model: HR 1.39, 95% CI 0.95–2.01). Sole PV infection was rare (n = 9) and the CI around the HR point estimate wide (fully adjusted model: HR 2.12, 95% CI 0.78–5.72). No interaction was found between malaria diagnosis and residence geography (p = 0.8) or age (p = 0.58).

**Fig. S2** depicts the survival curves stratified by malaria status and severity. Patients with severe malaria tended to have shorter survival than non-malaria and non-severe malaria groups, (log-rank test p = 0.001). Severe malaria patients, compared to individuals without malaria, had an increased adjusted risk for all-cause mortality (HR 1.51, 95% CI 1.24–1.84). The group with non-severe malaria, compared similarly, did not have an increase in mortality risk (HR 1.06, 95% CI 0.45–2.50), although CI are wide.

**Fig. 3** describes the adjusted ORs estimates for exploratory outcomes. Individuals with malaria had a greater risk for all-cause in-hospital mortality (OR 2.12, 95% CI 1.39–3.25), ICU admission (OR 1.46, 95% CI 1.02–2.09), and AKI (OR 1.52, 95% CI 1.06–2.18). The need of kidney replacement therapy (OR 1.0, 95% CI 0.59–1.69) and mechanical ventilation support (OR 1.36, 95% CI 0.90–2.05) did not differ between groups.

**Discussion**

**Principal findings**

The main finding of our study is the increased all-cause in-hospital mortality in critically-ill patients coinfected with SARS-CoV-2 and malaria treated in a tertiary COVID-19 referral center in Khartoum, Sudan. Point estimates of HRs were consistent across distinct malaria species. Our exploratory analyses demonstrated that AKI and ICU admission were more common among coinfected patients. Noteworthy, the median period between symptom onset and hospital admission was two days shorter in the malaria group, possibly reflecting some societal stigmatization of COVID-19.
Table 1
Descriptive statistics of the study population

| Demographics (No. (% of group)) | Without malaria | With malaria |
|----------------------------------|-----------------|--------------|
| Age, years mean (SD)             | 58.5 (17.3)     | 57.3 (15.0)  |
| Male                             | 232 (72.3)      | 214 (79.3)   |
| Sudanese nationality             | 309 (96.3)      | 261 (96.7)   |
| Khartoum resident                | 226 (70.4)      | 196 (57.8)   |

Comorbidities (No. found/No. available (% of available))

| Hypertension                     | 60/263 (22.8)   | 55/247 (22.3) |
| Diabetes                         | 102/320 (31.9)  | 111/270 (41.1) |
| Renal disease                    | 25/321 (7.8)    | 22/270 (8.1)  |
| Malignancy                       | 23/321 (7.2)    | 8/270 (3.0)   |
| HIV                              | 7/321 (2.2)     | 0/270 (0.0)   |
| Cardiovascular disease           | 57/320 (17.8)   | 41/269 (15.2) |
| Neurological Disease             | 19/320 (5.9)    | 23/270 (8.5)  |

Malaria species (No. (% of group))

| Plasmodium falciparum            | 0 (0.0)         | 140 (51.9)   |
| Plasmodium falciparum and Plasmodium vivax | 0 (0.0) | 121 (44.8)   |
| Plasmodium vivax                 | 0 (0.0)         | 9 (3.3)      |

COVID-19 symptoms (No. found/No. available (% of available))

| Primary COVID-19 contact identified* | 32/230 (13.9) | 38/142 (26.8) |
| Fever                              | 315/321 (98.1) | 266/270 (98.5) |
| Cough                              | 222/321 (69.2) | 216/270 (80.0) |
| Tiredness                          | 318/321 (99.1) | 270/270 (100.0) |
| Chest pain                         | 222/321 (69.2) | 182/270 (67.4) |

Fig. 2. Kaplan-Meier curves and number of patients at risk for all-cause in-hospital mortality.

Table 2
Hazard ratios for all-cause in-hospital mortality at different levels of adjustment

| Malaria status | No. (%) | Hazard Ratios (95% CI) | Model 1 | Model 2 | Model 3 b |
|----------------|---------|------------------------|---------|---------|-----------|
| Without malaria | 270 (46) | 1.74 (1.45–2.08) | 1.75 (1.46–2.11) | 1.43 (1.21–1.69) |
| With malaria | 270 (45.7) | 1.76 (1.24–2.50) | 1.77 (1.27–2.47) | 1.39 (0.95–2.01) |

Malaria species

| Plasmodium falciparum | 140 (52) | 1.71 (1.39–2.09) | 1.73 (1.36–2.19) | 1.45 (1.14–1.85) |
| Plasmodium vivax | 9 (3.0) | 2.03 (0.86–4.81) | 1.95 (0.84–4.51) | 2.12 (0.78–5.72) |
| Plasmodium falciparum and Plasmodium vivax | 121 (45) | 1.76 (1.24–2.50) | 1.77 (1.27–2.47) | 1.39 (0.95–2.01) |

Model 1: unadjusted. Model 2: adjusted for age and sex. Model 3: Model 2 plus hypertension, diabetes, and cardiovascular diseases.

* For malaria species, the denominator is 270 (number of malaria positive cases), whereas for malaria status it is the whole population (591).

b There were 23 missing data points (8.5%) for hypertension status among subject with malaria and 58 (18%) among non-malaria subjects. One patient in the non-malaria group (0.3%) had missing diabetes information.
Findings of the present study in light of previous publications

The impact of previous exposure to malaria on COVID-19 associated outcomes has been previously explored in heterogeneous settings with conflicting findings [10]. Early into the pandemic, ecological studies have suggested that countries where malaria is endemic tended to report lower SARS-CoV-2 infection rates and case fatality ratios [4,5]. These studies gave rise to claims of potential benefits of anti-malarial drugs (e.g. hydroxychloroquine) for COVID-19 treatment and prophylaxis. These claims have not been corroborated by subsequent randomized controlled trials [8,9]. Moreover, biological mechanisms by which immune response to previous malaria exposure could be protective against SARS-CoV-2 infection or severity were hypothesized, (e.g., a potential role of immunological memory against PF as a mediator for lower risk of COVID-19 [7]). Findings from translational research suggested cross-immunity between Plasmodium species and SARS-CoV-2 as biologically plausible mechanisms, as epitope mapping confirmed common antigens between PF and SARS-CoV-2 [6,13]. Another study suggested that malaria infection may lead to improved outcomes in patients with COVID-19, since SARS-CoV-2 clearance was faster in coinfected healthcare workers [14]. The clinical implications of these findings are uncertain and warrant longitudinal studies of clinical outcomes among coinfected subjects. A meta-analysis of observational data and case series indicated that patients previously exposed to malaria have more severe inflammation as indicated by C-reactive protein, procalcitonin, D-Dimer, and other inflammatory biomarkers; however, clinical outcomes have not been addressed [10]. The impact of coinfeciton on hematological and hepatic outcomes was reported in 12 patients with coinfeciton—hyperbilirubinemia and mild anemia were seen in four (33%) and two (17%) patients, respectively [10]. The rates of jaundice (2.1%) and severe anemia (3.8%) were lower in our cohort.

Strengths and limitations of the study

Our study has several strengths, first and foremost the availability of detailed health records and a well-organized, systematic, and robust testing strategy for both COVID-19 and malaria. Almost 93% of patients admitted to UCTC were tested for COVID-19 and malaria, mitigating bias by indication. In addition, the study population comprises patients from urban and rural areas. Exploring the impact of geography was motivated by well-known transportation and healthcare access challenges for patients residing outside Khartoum. We are not aware of data indicating a different epidemiological profile between Khartoum and other Sudanese cities regarding COVID-19 and malaria. Our analyses have some limitations. The observations come from a tertiary COVID-19 referral center and may not be generalizable to other care settings. The observational study design prevents us from excluding residual confounding. Additionally, we did not collect outcomes specific to COVID-19-associated complications, such as thrombotic events. We acknowledge that the influence of age and other comorbidities vs. malaria could be masked by the low proportion of young (<40 years), non-diabetic subjects. Lastly, we lack a quantitative measurement of Plasmodium parasitemia. Nevertheless, our findings are robust and add to the scarce literature on malaria and COVID-19 coinfection.

Implications for practice or policy and future research

Healthcare workers practicing in areas where malaria is endemic should always consider the possibility of coinfection with COVID-19 and malaria. Swift diagnosis is key, and we suggest a low threshold for malaria testing in patients with COVID-19 and residence in or recent travel to such areas. While we acknowledge limitations of using the WHO malaria severity classification in coinfected patients, our data show that applying these criteria may aid risk stratification
and prognostication. In patients with malaria, it is important to rapidly administer the regionally recommended anti-malarial regimen. As lung involvement can occur in both infections, we suggest computed tomography imaging of the lungs in coinfected patients to ascertain pulmonary pathologies [15]. If lung involvement is suggestive of COVID-19, specific therapeutic schemes (e.g., antivirals, monoclonal antibodies) should be considered, understanding that some therapeutics may be ineffective against specific SARS-CoV-2 variants and that there is no consensus evidence that a late administration of monoclonal antibodies or antivirals impacts outcome in hospitalized patients.

Our study challenges the notion that malaria mitigates the clinical course of COVID-19. We believe that specific care pathways for patients coinfected with COVID-19 and malaria are warranted. Importantly, national and international bodies should step up efforts to increase SARS-CoV-2 vaccination rates in areas where malaria is endemic. Future research into the clinical outcomes in non-hospitalized patients with malaria and COVID-19 coinfection is warranted to complement our findings.

Transparency declaration

PK is an employee of the Renal Research Institute, a wholly owned subsidiary of Fresenius Medical Care. PK receives author royalties from UpToDate and HSTalks and holds stock in Fresenius Medical Care. PK is on the Editorial Board of Blood Purification, Kidney and Blood Pressure Research, and Frontiers in Nephrology. PK is inventor on multiple patents in the field of kidney medicine. 

RPF is employed by Arbor Research Collaborative for health, who runs the DOPPS studies. Global support for the ongoing DOPPS Programs is provided without restriction on publications by a variety of funders. Funding is provided to Arbor Research Collaborative for Health and not to RPF directly. For details see https://www.dopps.org/AboutUs/Support.aspx. RPF receives research grants from Fresenius Medical Care, National Council for Scientific and Technological Development, honoraria (paid to employer) from AstraZeneca, Boehringer-Lilly, Novo Nordisk, Akebia, Bayer for participation in advisory Boards and educational activities.

All other authors have declared no conflict of interest. No external funding was received.

Ethics committee approval

The study proposal was submitted to the Research Administration at the State Ministry of Health (MOH), Khartoum. Expedited review was conducted by the MOH Ethics Review Committees and approval was granted (protocol COVID-19/001/2020).

Data sharing

The datasets used in the current study are available from the authors in an anonymized format upon reasonable request.

Author’s contributions

Conceptualization: RH, RPF, PK; Data curation: RH; Formal analysis: MG, PK; Investigation: MG, PK; Methodology: RH, MG, RPF, PK; Project administration: RH, NI, MMA, AET, NA, HA; Software: RH, GM, NI, MMA, AET, NA, HA, PK; Supervision: RH, NA, HA; Validation: RH, NI, MMA, AET, NA, HA; Writing – original draft: RH, GM, RPF, PK; Writing – review & editing: all authors.

Acknowledgements

The authors express their gratitude to UCTC health professionals and administrative staff, and the study participants. The authors appreciated the administrative help of Maggie Han, Renal Research Institute, New York, NY.

This manuscript is part of a PhD thesis of RH, at the School of Medicine, Pontificia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil. RH has been scientist-in-residence at the Renal Research Institute, New York, N; she is a mentee of PK as part of the International Society of Nephrology (ISN) Mentorship Program and the collaboration between Soba University Hospital and PUCPR has been supported by the ISN’s Sister Renal Center.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2022.03.028.

References

[1] Josephson A, Kilic T, Michler JD. Socioeconomic impacts of COVID-19 in low-income countries. Nat Hum Behav 2021;5:557–65.
[2] Bottan N, Hoffman B, Vera-Cossio DA. The unequal impact of the coronavirus pandemic: evidence from seventeen developing countries. Inter-American Development Bank; 2020 [cited 27 Oct 2021]. Available from: https://publications.iadb.org/en/the-unequal-impact-of-the-coronavirus-pandemic-evidence-from-seventeen-developing-countries.
[3] Okeereke M, Ukor NA, Nwanyuya LM, Mwansa C, Alhaj SM, Ogunkola IO, et al. COVID-19 misinformation and misinformation in rural Africa. Am J Trop Med Hyg 2020;104:453–6.
[4] Hussein MIH, Albashir AAD, Elsadig O, Honeida A. Malaria and COVID-19: unmasking their ties. Malar J 2020;19:457.
[5] Napoli PE, Nioi M. Global spread of Coronavirus Disease 2019 and malaria: an epidemiological paradox in the early stage of a pandemic. J Clin Med 2020;9:1138.
[6] Iesa MAM, Osman MEM, Hassan MA, Dirar AIA, Abuzzi MA, Mancuso JJ, et al. SARS-CoV-2 and Plasmodium falciparum common immunodominant regions may explain low COVID-19 incidence in the malaria-endemic belt. New Microbe. New Infect 2020:38:100817.
[7] Kalungi A, Kinyanda E, Akena DH, Kaleebu P, Bisangwa IM. Less severe cases of COVID-19 in Sub-Saharan Africa: could co-infection or a recent history of Plasmodium falciparum infection be protective? Front Immunol 2021;12:565625.
[8] Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Basabi M, Loefgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med 2020;173:623–31.
[9] Mitja O, Corbacho-Monné N, Ubals M, Tebe C, Peñañuel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clin Infect Dis 2021;73:e4073–81.
[10] Wilaratana P, Masangkay FR, Kotepui KU, Milanez GJ, Kotepui M. Prevalence and characteristics of malaria among COVID-19 individuals: a systematic review, meta-analysis, and analysis of case reports. PLoS Negl Trop Dis 2021;15: e0006766.
[11] Severe malaria. Trop Med Int Health 2014;19:7–131.
[12] Khwaja A. KDIGO clinical practice guideline for acute kidney injury. Nephron Clin Pract 2012;120:e179–84.
[13] Schofield L, Mueller I. Clinical immunity to malaria. Curr Mol Med 2006;6:205–21.
[14] Mahajan NN, Gajbhiye RK, Bahirat S, Lokhande PD, Mathe A, Rathi S, et al. Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare workers. J Med Virol 2021;93:2431–8.
[15] Zhou X, Pu Y, Zhang D, Xia Y, Guan Y, Li S, et al. CT findings and dynamic imaging changes of COVID-19 in 2008 patients: a systematic review and meta-analysis. Acta Radiol 2022;63:291–310.